Ratings by Brookline Capital Markets (Tyler Bussian)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/17/2025 | Cardiol Therapeutics | CRDL | New Coverage | Buy (N/A) |
1.08 (0.97) |
-10.19% | Details | |
| 3/21/2025 | Cognition Therapeutics | CGTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2025 | BioVie Inc. | BIVI | New Coverage | Buy (N/A) |
1.10 (1.36) |
23.64% | Details | |
| 3/17/2025 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2025 | CervoMed | CRVO | Upgrade | Buy (Hold) |
2.22 (4.11) |
85.14% | Details | |
| 12/10/2024 | CervoMed | CRVO | Downgrade | Hold (Buy) |
10.25 (2.22) |
-78.34% | Details | |
| 11/19/2024 | Envoy Medical | COCH | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2024 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2024 | CervoMed | CRVO | New Coverage | Buy (N/A) |
15.50 (4.11) |
-73.48% | Details | |
| 4/5/2024 | Immunic Inc. | IMUX | New Coverage | Buy (N/A) |
1.22 (1.23) |
0.82% | Details | |
| 2/28/2024 | Annovis Bio Inc. | ANVS | Downgrade | Hold (Buy) |
8.87 (2.49) |
-71.93% | Details | |
| 11/10/2023 | Annovis Bio Inc. | ANVS | New Coverage | Buy (N/A) |
5.79 (2.49) |
-56.99% | Details |
